EMEA Recommends Approval For Astellas’ Mycamine
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21